Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-75
SponsorImperial College London

About this trial

The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses.

The main questions the study aims to answer are:

* What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop more severe illness and exacerbations? * Can treatments be identified that target these processes to reduce the severity and frequency of exacerbations in people with COPD?

The study will compare eligible participants with COPD to healthy volunteers, and will involve intentionally infecting each participant with rhinovirus in a controlled environment. They will undergo baseline investigations prior to infection including a first bronchoscopy. Post-infection each participant will undergo a range of tests, including a second bronchoscopy, to compare how processes in the body, and especially the lungs, differ between people who do and do not have COPD.

Eligibility criteria

Qualifiers

Male or female sex

Age ≥40 years and ≤75 years at the time of signing the consent form

Medical history or clinical diagnosis of COPD

Cumulative smoking history of at least 20 pack years

Disqualifiers

Bronchiectasis including cystic fibrosis

Bronchiolitis obliterans

Carcinoma of the bronchus

Fibrosis such as tuberculosis (TB), idiopathic pulmonary fibrosis

Trial design

Treatments tested in this trial

  • Rhinovirus-A16

Treatment groups

50 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Imperial College London

Lead sponsor

Imperial College Healthcare NHS Trust

Collaborator